Cytokinetics EVP exercises options, sells 15,000 shares

Cytokinetics executive Andrew Callos reported an option exercise and share sale.

Rhea-AI Filing Summary

Cytokinetics executive Andrew Callos reported an option exercise and share sale. On 02/05/2026, the EVP and Chief Commercial Officer exercised 15,000 non-qualified stock options at $23.26 per share and received 15,000 shares of common stock.

That same day, he sold 15,000 shares of common stock at $61.93 per share, leaving him with 50,440 shares of common stock held directly and 84,000 stock options remaining. The reported options were originally granted on 03/31/2022 and are scheduled to vest over four years, with an expiration date of 03/31/2031.

Insider Trade Summary

Exercise and Sale: 15,000 shares ($580K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 15,000 shs ($929K)

Approx. gross sale proceeds $929K

Approx. exercise cost $349K

Approx. pre-tax spread $580K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$23.26	$349K
Sale	Common Stock	15,000	$61.93	$929K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 84,000 contracts (Direct); Common Stock — 50,440 shares (Direct)

Footnotes (1)

1. F1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Andrew Callos report at Cytokinetics (CYTK)?

Andrew Callos reported exercising 15,000 stock options and selling 15,000 Cytokinetics common shares on 02/05/2026. The exercise was at $23.26 per share and the sale at $61.93 per share, reflecting a same-day option exercise and share sale by the company’s EVP, Chief Commercial Officer.

How many Cytokinetics (CYTK) shares does Andrew Callos own after this Form 4?

After the reported transactions, Andrew Callos directly owns 50,440 shares of Cytokinetics common stock. He also holds 84,000 non-qualified stock options, according to the filing, giving him both current share ownership and additional potential equity exposure through derivative securities.

At what prices did Andrew Callos exercise and sell Cytokinetics (CYTK) shares?

Andrew Callos exercised 15,000 non-qualified stock options at $23.26 per share and sold 15,000 Cytokinetics common shares at $61.93 per share on 02/05/2026. These prices come directly from the transaction details in the Form 4 filing tables.

What type of derivative security did Andrew Callos exercise at Cytokinetics (CYTK)?

He exercised a non-qualified stock option (right to buy) covering 15,000 shares of Cytokinetics common stock. The option has an exercise price of $23.26 per share, was granted on 03/31/2022, and carries an expiration date of 03/31/2031, with vesting over four years.

How do Andrew Callos’s Cytokinetics (CYTK) stock options vest?

The options vest over four years from the 03/31/2022 grant date. One quarter of the shares vest on the first anniversary, and the remaining three quarters vest monthly at 1/48th over the next 36 months, subject to his continued employment with Cytokinetics.

What role does Andrew Callos hold at Cytokinetics (CYTK) in this Form 4?

In the Form 4, Andrew Callos is identified as an officer of Cytokinetics, specifically serving as EVP, Chief Commercial Officer. The filing indicates he is not a director and not a 10% owner, but a Section 16 reporting officer of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 08:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		M		15,000	A	$23.26	65,440	D
Common Stock	02/05/2026		S		15,000	D	$61.93	50,440	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$23.26	02/05/2026		M			15,000	03/31/2022(1)	03/31/2031	Common Stock	15,000	$0	84,000	D

Explanation of Responses:

1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.